Determination of Regulatory Review Period for Purposes of Patent Extension; CERVARIX

Federal Register

A Notice by the Food and Drug Administration on 03/09/2011

The Food and Drug Administration (FDA) has determined the regulatory review period for CERVARIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.

Read More